Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Sanofi Set to Expand Drug Portfolio and Presence in India, Plans Strategic Overhaul
In line with its expansion plans, Sanofi is exploring partnerships with key Indian pharmaceutical companies such as Cipla, Dr. Reddy’s Laboratories, and Emcure to facilitate wider access to its products.
French pharmaceutical giant Sanofi is gearing up to introduce several top-selling drugs from its global pipeline in India, as per recent news reports. The company is reportedly strategizing to enhance its operations in the country.
As reported by various news outlets, Sanofi aims to significantly broaden its footprint in India, considering it as an "under-represented market." The company is said to be ambitious about its plans to strengthen its presence further.
As part of its revamped strategy, Sanofi intends to launch various new products, including Soliqua, a pre-mix insulin drug, and Xenpozyme, used for treating late-onset Pompe disease. The pharmaceutical major also disclosed its plans to introduce Dupixent, designed for eczema in adults, Beyfortus for respiratory viruses, and Mexiviazyme.
This strategic shift is expected to enhance accessibility to Sanofi's existing product range in India, which comprises Lantus, Clexane, Targocid, Allegra, Enterogermina, Combiflam, Cardace, and Cerezyme.
In line with its expansion plans, Sanofi is exploring partnerships with key Indian pharmaceutical companies such as Cipla, Dr. Reddy’s Laboratories, and Emcure to facilitate wider access to its products.
Recently, the company announced a collaboration with Dr. Reddy’s to promote and distribute pediatric and adult vaccine brands including Hexaxim, Pentaxim, and Tetraxim.
Sanofi is set to distribute its Central Nervous System (CNS) product range in India, encompassing six brands, including Frisium anti-epileptic drugs, through its partnership with Cipla.